Artigos de revistas: "Conference (1926 : Philadelphia, Pa.)"

1

O'Keefe, Thomas, Christina Yau, Emma Iaconetti, Eliza Jeong, Case Brabham, Paul Kim, Joseph McGuire et al. "Abstract PR008: Duration of endocrine treatment for DCIS impacts second events: Insights from a large registry of cases at two academic medical centers". Cancer Prevention Research 15, n.º 12_Supplement_1 (1 de dezembro de 2022): PR008. http://dx.doi.org/10.1158/1940-6215.dcis22-pr008.

Texto completo da fonte

Resumo:

Abstract Background: Ductal carcinoma in situ (DCIS) incidence has risen with increasing use of screening mammography. It is unclear who benefits from both the amount and type of adjuvant treatment (radiation therapy, (RT), endocrine therapy (ET)) versus what constitutes over-treatment. Our goal was to identify the effects of adjuvant RT, or ET+/- RT versus breast conservation surgery (BCS) alone in a large multi-center DCIS registry of retrospective patients with long follow up. Methods: Data was extracted on women with a primary diagnosis of DCIS (N=2979) between 1985 - 2017 treated in 2 University of California (UC) medical centers. ET treatment and duration was confirmed by chart review for 1916 patients for this analysis. Receipt of ET (N=404) was stratified to > 2 years or < 2 years. Association between treatment type and second events was assessed using Cox regression. Competing risks models were used to assess effect of treatment type on different type of second events (ipsilateral DCIS or invasive, or contralateral combined). Time-varying coefficients were used as appropriate. Results: Median follow up time was 8.2 years for the 1916 patients analyzed. The cumulative second event (any type) rate was 25% at 15 years. In univariate and multivariate analysis adjusting for clinical variables, all treatments reduced the risk of second events compared to BCS only. Further stratifying ET receipt by duration demonstrated significant risk reduction (HR=0.12, P=0.04) only in women taking >2 years of ET, but not in women in the <2year ET group (HR=1.3, P=0.55). In the competing risk model, RT significantly reduces the risk of both ipsilateral DCIS and invasive cancer, and ET > 2 years significantly reduces the risk of ipsilateral invasive cancer. Conclusions: In our registry we show that women with DCIS who took less than 2 years of adjuvant endocrine therapy have a similar second event rate as BCS. In contrast, women who took more than 2 years of ET show a significantly reduced second event rate, similar to those who received either RT or combined ET+RT, which was independent of age, tumor size, grade, or period of diagnosis. This highlights the importance of ET duration for risk reduction of second events following surgery for newly diagnosed DCIS. Citation Format: Thomas O'Keefe, Christina Yau, Emma Iaconetti, Eliza Jeong, Case Brabham, Paul Kim, Joseph McGuire, Ann Griffin, Laura Esserman, Olivier Harismendy, Gillian Hirst. Duration of endocrine treatment for DCIS impacts second events: Insights from a large registry of cases at two academic medical centers [abstract]. In: Proceedings of the AACR Special Conference on Rethinking DCIS: An Opportunity for Prevention?; 2022 Sep 8-11; Philadelphia, PA. Philadelphia (PA): AACR; Can Prev Res 2022;15(12 Suppl_1): Abstract nr PR008.

Estilos ABNT, Harvard, Vancouver, APA, etc.

2

Smith, Randall S., Andrea Jewell, Evrosina Isaac e Jennifer M. Rohan. "Abstract B090: Relationship between medication adherence, psychosocial risk, and sociodemographic characteristics in pediatric cancer". Cancer Epidemiology, Biomarkers & Prevention 32, n.º 1_Supplement (1 de janeiro de 2023): B090. http://dx.doi.org/10.1158/1538-7755.disp22-b090.

Texto completo da fonte

Resumo:

Abstract Background/Purpose: The purpose of this study is to examine the relationship between sociodemographic characteristics (e.g., minority status, geographic location), psychosocial risk, and medication adherence in pediatric cancer. Methods: This study included 40 pediatric oncology patients ages 2-19 years (Mage=11.6±5.6 years) in active treatment. 52.5% identified as non-Hispanic White, 32.5% identified as non-Hispanic minority, and 15% identified as Hispanic. Parents completed the Psychosocial Assessment Tool (PAT) at baseline assessing psychosocial risk factors. Patients used objective adherence monitors (MEMS) , which recorded daily adherence rates to chemotherapy and non-chemotherapy medications across one year. Results: The PAT identified that 55% of patients needed universal intervention and 45% needed targeted clinical interventions. Patients identified as lowest psychosocial risk (i.e., needing universal interventions), had significantly higher adherence rates (M=74%±22%) than those identified as highest psychosocial risk (i.e., needing targeted interventions; M=51%±37%; p < 0.004). While non-minoritized White patients demonstrated higher rates of treatment adherence (M=71%±32%) compared to minoritized patients (M=56%±31%); this finding was not significant. Additionally, there was no significant difference between geographic distance from hospital and medication adherence. In fact, those who lived closer to the hospital had lower adherence rates (M=62%±31%) compared to those who lived further away (M=67%±34%). There also was no significant difference between distance from hospital and psychosocial risk. Patients identified as greatest psychosocial risk (i.e., in need of targeted interventions) only lived 3 miles further from the hospital (M=27.1±26.6 miles) than those in need of preventative interventions (M=24.2±19.6 miles). Conclusions & Implications: The geographic location of pediatric oncology patients in relation to the hospital at which they received treatment did not significantly impact treatment adherence to chemotherapy and non-chemotherapy medications. Furthermore, minority status did not significantly affect treatment adherence rates. On the other hand, treatment adherence was significantly lower for patients whose parents reported more psychosocial stressors. Future research should identify innovative health promotion interventions targeting psychosocial risk, which seems to have the greatest influence on health behaviors like medication adherence. Citation Format: Randall S. Smith, Andrea Jewell, Evrosina Isaac, Jennifer M. Rohan. Relationship between medication adherence, psychosocial risk, and sociodemographic characteristics in pediatric cancer [abstract]. In: Proceedings of the 15th AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved; 2022 Sep 16-19; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2022;31(1 Suppl):Abstract nr B090.

Estilos ABNT, Harvard, Vancouver, APA, etc.

3

Carter, Brian J., Tzuan A. Chen, Dalnim Cho, Lorna H. McNeill, Shahnjayla K. Connors e Lorraine R. Reitzel. "Abstract A099: Black church-goers who most recently sought cancer information from certain sources are less likely to have ever undergone colorectal cancer screening and thus less likely to benefit from early detection". Cancer Epidemiology, Biomarkers & Prevention 32, n.º 1_Supplement (1 de janeiro de 2023): A099. http://dx.doi.org/10.1158/1538-7755.disp22-a099.

Texto completo da fonte

Resumo:

Abstract Purpose: Black adults have the highest colorectal cancer (CRC) incidence and mortality rates of any racial group in America. Early detection through CRC screening may improve survival outcomes; however, CRC screening uptake is lower for Black adults than White adults. To uncover opportunities to address these inequities, we examine where Black adults prefer to obtain cancer information, where they most recently sought such information, and whether either was associated with CRC screening behavior. Methods: Participants were a convenience sample of Black men and women recruited from 3 churches in Houston, Texas. Self-reported data included preferred source of cancer information (doctor or health care provider (collectively, “providers”), cancer organization, social network, internet, or “other media” (i.e., books, brochures, pamphlets, the library, magazines, newspapers)), most recent source of cancer information (same categories as preferred), and having ever been screened for CRC. A logistic regression model controlling for recruitment site, sociodemographic variables (e.g., sex, education), personal and family history of cancer, worries and perceptions about cancer risk, and satisfaction with patient-provider communication examined associations between preferred and most recent source of cancer information, respectively, and CRC screening behavior. Results: The sample included 751 Black adults aged >50 (Mage=59.1+6.6, 24% male), with data collected before the pandemic. Overall, 57.9% of respondents indicated their preferred source of cancer information was a provider, 19.6% the internet, 11.5% other media, 10% a cancer organization, and 1.1% their social network. Overall, 21% indicated their most recent source of cancer information was a provider, 57.3% the internet, 13.5% other media, 4.7% a cancer organization, and 3.6% their social network. About 83.6% of participants had ever been screened for CRC. Results indicated that those who most recently sought information from other media had lower odds of having ever been screened for CRC than those who most recently sought information from a provider (aOR: 0.489, CI95%: 0.245-0.976). There were no significant associations between preferred source of cancer information and CRC screening behavior. Conclusion: These results reveal an opportunity to encourage Black church-goers to obtain cancer information from providers rather than from other media as a method to enhance CRC screening use. Encouragement to seek this information directly from a provider could, for example, come from health ministries, church newsletter or email communications, the church’s website, and/or the pulpit. These results also reveal an opportunity to investigate what modifiable social determinants or other factors prevent Black church-goers from seeking cancer screening information from their provider as opposed to other media, especially considering most of the sample preferred to get this information from a provider, as one part of a multi-pronged approach to help mitigate racial inequities in CRC screening behavior. Citation Format: Brian J. Carter, Tzuan A. Chen, Dalnim Cho, Lorna H. McNeill, Shahnjayla K. Connors, Lorraine R. Reitzel. Black church-goers who most recently sought cancer information from certain sources are less likely to have ever undergone colorectal cancer screening and thus less likely to benefit from early detection [abstract]. In: Proceedings of the 15th AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved; 2022 Sep 16-19; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2022;31(1 Suppl):Abstract nr A099.

Estilos ABNT, Harvard, Vancouver, APA, etc.

4

Lalonde, Chloe S., Jeffrey M. Switchenko, Madhusmita Behera, Mehmet A. Bilen, Taofeek K. Owonikoko, Colleen M. Lewis, Elise Hitron et al. "Abstract B085: Shifting sociodemographic characteristics of a phase 1 oncology clinical trial population at an NCI-designated Comprehensive Cancer Center in the Southeast in comparison to its catchment area". Cancer Epidemiology, Biomarkers & Prevention 32, n.º 1_Supplement (1 de janeiro de 2023): B085. http://dx.doi.org/10.1158/1538-7755.disp22-b085.

Texto completo da fonte

Resumo:

Abstract Background: Racial and ethnic minority populations are consistently under-represented in oncology clinical trials despite comprising a disproportionate share of cancer burden. Due in part to difficulties associated with participation, phase 1 (P1) oncology trials pose a unique challenge and opportunity for minority inclusion. Here we examine the sociodemographics of P1 cancer clinical trial patients at an NCI-designated Comprehensive Cancer Center compared to all patients treated at the center, patients with new cancer diagnoses in metropolitan Atlanta (ATL), and the state of Georgia (GA). Methods: Patients enrolled on P1 trials at the Winship Cancer Institute (WCI) from 2015- 2020, identified from a data warehouse, were compared to new patient registrations at WCI from 2015-2020. Patients with cancer in metro ATL and GA were identified from the SEER Nov 2018 Submission. Covariates for the P1 and WCI institutional cohorts included sex, race, insurance, zip code. Covariates for SEER patients included sex and race. Median income by zip code per Census 2020 data was divided in quartiles per Census 2020 GA income distribution. Summary statistics are reported for categorical variables using frequencies and percentages. Comparisons between groups were conducted using one-sample proportion tests. Trends were assessed using the Cochran-Armitage test. Results: From 2015-2020, 2325 patients (43.4% F, 56.6% M) signed consent for P1 trials. Grouped race distribution was 70.3% White, 26.2% Black, 3.5% Other. Insurance distribution was 42.9% private, 48% government, 9.1% uninsured/other. Of new patient registrations at WCI from 2015-2020 (N=107497) (50.0% F, 50.0% M), grouped race distribution was 63.3% W, 32.0% B, 4.7% O. ATL 2015 SEER patients (N=31101) (50.3%F, 49.7%M) showed grouped race distribution 58.4% W, 37.2% B, 4.3% O. GA 2015 SEER patients (N=99487) (48.6%F, 51.4%M) showed grouped race distribution 71.2% W, 26.7% B, 2.1% O. Race and sex distribution of P1 patients was significantly different than WCI and ATL SEER patients (p< 0.001). Comparing the P1 and WCI groups from 2015-2020, percent female did not change over time in either group (p=0.54 P1; p=0.063 WCI). Percentage of white patients did decrease over time in both groups (p=0.009 P1; p<0.001 WCI). Percent of P1 patients with private insurance was higher than the WCI group (p<0.001). Percent of P1 and WCI patients living in zip codes with lower median household income (Q1 & Q2) were 19.6% and 20.4%, respectively (p=0.41). Conclusions: Although P1 patients at WCI were more likely to be white, male, and privately insured, from 2015-2020, the percentage of white patients in P1 oncology clinical trials and amongst all new cancer patients treated at WCI decreased significantly. This data serves to initially characterize the existing racial disparities in oncology clinical trials in metro ATL and GA, and will lead to further understanding to ultimately improve representation of patients from racial and ethnic minority backgrounds in P1 clinical trials in our catchment area. Citation Format: Chloe S. Lalonde, Jeffrey M. Switchenko, Madhusmita Behera, Mehmet A. Bilen, Taofeek K. Owonikoko, Colleen M. Lewis, Elise Hitron, Hannah Collins, Tracy B. Goodale, Emma C. Judson, Ludimila Cavalcante, R. Donald Harvey, Jennifer W. Carlisle. Shifting sociodemographic characteristics of a phase 1 oncology clinical trial population at an NCI-designated Comprehensive Cancer Center in the Southeast in comparison to its catchment area [abstract]. In: Proceedings of the 15th AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved; 2022 Sep 16-19; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2022;31(1 Suppl):Abstract nr B085.

Estilos ABNT, Harvard, Vancouver, APA, etc.

5

Telles, Victoria M., Mateo Banegas e David Strong. "Abstract B131: Social drivers of adverse health outcomes among cancer survivors". Cancer Epidemiology, Biomarkers & Prevention 32, n.º 12_Supplement (1 de dezembro de 2023): B131. http://dx.doi.org/10.1158/1538-7755.disp23-b131.

Texto completo da fonte

Resumo:

Abstract Purpose of the Study Disparities in health outcomes among cancer survivors are often driven by differences in social-ecological resources. Poor health outcomes and multiple chronic conditions often manifest as a result of shared demographic and social risk factors. The aim of this study was to examine the social drivers that predict adverse health outcomes among cancer survivors. Methods Data from the national longitudinal Population Assessment of Tobacco and Health (PATH) Study was used to examine social drivers of several adverse health outcomes: tobacco use, sleep trouble, high cholesterol, diabetes, and high blood pressure among cancer survivors enrolled in the first cohort (waves 1-3; n=1924). Social drivers included education, financial stress, poverty level, insurance status, and satisfaction with social relationships. Survey-weighted multivariable logistic regression was used to assess demographic and social drivers that predicted health outcomes among cancer survivors. Results Among the 1,924 cancer survivors, most were non-Hispanic, White (77%); 56% female; ages ranged from 18-34 (14%), 35-54 (27%), 55-64 (24%), 65+ (34%). Higher tobacco use was linked (p’s<0.05) to both demographic (males, younger) and social drivers (lower education, poverty, lack of insurance and social dissatisfaction). Trouble sleeping was associated with social drivers including financial stress (p<.001) and social dissatisfaction (p<.0001). High cholesterol was significantly associated with demographics (older age) and social drivers including lower education, access to insurance, and social dissatisfaction (p’s<.05). High blood sugar was significantly associated with demographics (older age, NH Black) and social drivers (lower education and social dissatisfaction (p’s<.05). High blood pressure was significantly associated with demographic (older age, male, NH Black) and social drivers including lower education college (p<.05) and financial stress (p<.05). Conclusions Increased recognition of the critical role of social drivers on health outcomes suggests effective interventions that are sensitive to cancer survivors’ social-ecological contexts are needed to improve health equity and reduce cancer health disparities. Citation Format: Victoria M. Telles, Mateo Banegas, David Strong. Social drivers of adverse health outcomes among cancer survivors [abstract]. In: Proceedings of the 16th AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved; 2023 Sep 29-Oct 2;Orlando, FL. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2023;32(12 Suppl):Abstract nr B131.

Estilos ABNT, Harvard, Vancouver, APA, etc.

6

Vasthu, Durango. "Global Supply Chain Management Conference". International Journal of Risk and Contingency Management 1, n.º 1 (janeiro de 2012): 64–65. http://dx.doi.org/10.4018/ijrcm.2012010105.

Texto completo da fonte

Resumo:

The 2011 annual ‘big event’ in the global supply chain industry was held in Philadelphia PA USA during the week of October 2-5. This event is organized each year, and is the official global meeting, for the Council of Supply Chain Management Professionals (CSCMP, http://cscmp.org/events/annual-global/sessionsearch-after.asp). The conference featured risk-related topics ranging from inventory forecasting to reverse logistics planning in globally-impacted markets.

Estilos ABNT, Harvard, Vancouver, APA, etc.

7

Johnson, Wenora Y. "Abstract IA002: How patient advocates can make a difference in their research advocacy efforts and contributions and why it's important". Cancer Epidemiology, Biomarkers & Prevention 32, n.º 1_Supplement (1 de janeiro de 2023): IA002. http://dx.doi.org/10.1158/1538-7755.disp22-ia002.

Texto completo da fonte

Resumo:

Abstract Knowledge about cancer research has driven me to advocate on behalf of myself and others who need to know about their cancer risk, hereditary pre-disposition, prevention and survivorship. Understanding how Patient Advocates can make a difference is extremely important and valuable to research. Citation Format: Wenora Y. Johnson. How patient advocates can make a difference in their research advocacy efforts and contributions and why it's important [abstract]. In: Proceedings of the 15th AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved; 2022 Sep 16-19; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2022;31(1 Suppl):Abstract nr IA002.

Estilos ABNT, Harvard, Vancouver, APA, etc.

8

Drage, Michael G. "Abstract IA005: Artificial intelligence for breast pathology: Challenges and opportunities (and more challenges!)". Cancer Prevention Research 15, n.º 12_Supplement_1 (1 de dezembro de 2022): IA005. http://dx.doi.org/10.1158/1940-6215.dcis22-ia005.

Texto completo da fonte

Resumo:

Abstract This presentation will review some fundamental aspects of breast pathology, introduce PathAI’s approach to building algorithms for computer vision applications, and highlight some applications where AI has shown capacity to yield clinically-relevant insights from breast cancer specimens. I will also highlight some interesting challenges in breast pathology practice pertinent to intraductal proliferations, and how these challenges are beginning to be addressed in the field of AI. Citation Format: Michael G. Drage. Artificial intelligence for breast pathology: Challenges and opportunities (and more challenges!) [abstract]. In: Proceedings of the AACR Special Conference on Rethinking DCIS: An Opportunity for Prevention?; 2022 Sep 8-11; Philadelphia, PA. Philadelphia (PA): AACR; Can Prev Res 2022;15(12 Suppl_1): Abstract nr IA005.

Estilos ABNT, Harvard, Vancouver, APA, etc.

9

Ashour, Ahmed M., Amro M. Al-Omari, Mohammad S. Bani Amer e Zaid R. Kamal. "Abstract A010: Insights into the Impact of Fanconi Anemia Repair Genes on Immunotherapy Response in Solid Tumors". Cancer Research 84, n.º 1_Supplement (9 de janeiro de 2024): A010. http://dx.doi.org/10.1158/1538-7445.dnarepair24-a010.

Texto completo da fonte

Resumo:

Abstract Title: Insights into the Impact of Fanconi Anemia Repair Genes on Immunotherapy Response in Solid Tumors Background: Fanconi anemia repair (FAR) genes have crucial involvement in determining immunogenicity of solid tumors due to their substantial involvement in DNA damage repair (DDR). Previous work has alluded to the significance of DDR pathways such as mismatch repair and homologous recombination genes in treatment guidance. Herein, we study the potential impact of FAR genes mutations on immunotherapy parameters in solid tumors. Methods: We used the MSK immunotherapy and Tumor Mutational Burden (TMB) dataset was used in our analysis, which includes mutational and clinical data for 1661 patients on immune checkpoint inhibitors (anti-PD-1/L1, anti-CTLA-4, or combinational therapy) from ten cancer types (bladder, breast, colorectal, esophagogastric, glioma, head and neck, melanoma, non- small cell lung, renal cell, and unknown primary cancer). All clinical ang genomic data was retrieved through the cBioPortal database. Patients were categorized into the FAR mutated group if they harbored a mutation in at least one of the FAR genes (FANCA, FANCC, BRCA2, BRIP1, PALB2, RAD51C, SLX4) included in the MSK-IMPACT targeted next-generation sequencing panel. The log rank test and the Wilcoxon test, Chi-squared test were used to compare overall survival (OS), continuous and categorical data between FAR mutated and wildtype groups. Results: The MSK TMB cohort included 220 (13%) patients with FAR mutations, of which melanoma comprised the highest percentage (26.4%) followed by non-small cell lung cancer (NSCLC; 19.6%). The most common altered FAR gene was BRCA2 (6%), followed by SLX4 (5%), while the least altered gene was RAD51C (0.7%). FAR mutated patients had significantly higher OS compared to the wildtype group (median OS (mOS): 29 vs 17 months, log rank p < 0.001). Among melanoma patients (n = 320), there was no significant difference in OS between the mutated and FAR groups, whereas the NSCLC (n = 350) and colorectal cancer (CRC, n = 110) subgroups had significantly higher OS in the FAR mutated groups (NSCLC - mOS: 19 vs 10 months, p = 0.0256, CRC – mOS: not reached vs 13 months, p &l; 0.001). TMB was significantly higher in the FAR mutated group (median TMB: 22.3 vs 5.2, p < 0.001). Notably, the most frequent co-mutations in the FAR mutated group included CTLA4, STK19, E2F3, CD276, MYCL. Conclusion: Our analysis highlights the potential role of FAR genes mutations in predisposing solid tumor patients to ICI benefit, specifically in NSCLC and CRC patients. Insights into the potential interactions between FAR genes and other DDR pathways as well as their impact on tumor immune microenvironment parameters are needed in future research to understand the drivers of ICI benefit in this subset of patients. Citation Format: Ahmed M. Ashour, Amro M. Al-Omari, Mohammad S. Bani Amer, Zaid R. Kamal. Insights into the Impact of Fanconi Anemia Repair Genes on Immunotherapy Response in Solid Tumors [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: DNA Damage Repair: From Basic Science to Future Clinical Application; 2024 Jan 9-11; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2024;84(1 Suppl):Abstract nr A010.

Estilos ABNT, Harvard, Vancouver, APA, etc.

10

Sharma, Hari, Stephen Skaper e Aruna Sharma. "Conference Report: 7th Clinical Trials on Alzheimer’s Disease Annual Conference, Philadelphia, PA, USA Nov 20-22, 2014". CNS & Neurological Disorders - Drug Targets 14, n.º 1 (1 de fevereiro de 2015): 7–10. http://dx.doi.org/10.2174/1871527314666150130155536.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

11

Leighow, Scott M., Haider Inam e Justin R. Pritchard. "Abstract B007: Design and construction of evolutionary-guided "selection gene drive" therapy". Cancer Research 82, n.º 10_Supplement (15 de maio de 2022): B007. http://dx.doi.org/10.1158/1538-7445.evodyn22-b007.

Texto completo da fonte

Resumo:

Abstract This abstract is being presented as a short talk in the scientific program. A full abstract is available in the Proffered Abstracts section (PR014) of the Conference Proceedings. Citation Format: Scott M. Leighow, Haider Inam, Justin R. Pritchard. Design and construction of evolutionary-guided "selection gene drive" therapy [abstract]. In: Proceedings of the AACR Special Conference on the Evolutionary Dynamics in Carcinogenesis and Response to Therapy; 2022 Mar 14-17. Philadelphia (PA): AACR; Cancer Res 2022;82(10 Suppl):Abstract nr B007.

Estilos ABNT, Harvard, Vancouver, APA, etc.

12

Dawson, Michelle R., e Deepraj Ghosh. "Abstract A002: Physical and metabolic aspects of therapy induced senescence and polyploidy in an evolving tumor microenvironment". Cancer Research 83, n.º 2_Supplement_1 (15 de janeiro de 2023): A002. http://dx.doi.org/10.1158/1538-7445.agca22-a002.

Texto completo da fonte

Resumo:

Abstract This abstract is being presented as a short talk in the scientific program. A full abstract is available in the Short Talks from Proffered Abstracts section (PR007) of the Conference Proceedings. Citation Format: Michelle R. Dawson, Deepraj Ghosh. Physical and metabolic aspects of therapy induced senescence and polyploidy in an evolving tumor microenvironment [abstract]. In: Proceedings of the AACR Special Conference: Aging and Cancer; 2022 Nov 17-20; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2022;83(2 Suppl_1):Abstract nr A002.

Estilos ABNT, Harvard, Vancouver, APA, etc.

13

Watson, Nyeema, e Jennifer Johnson Kebea. "All In: The Urban Mission". Metropolitan Universities 31, n.º 2 (20 de julho de 2020): 3–6. http://dx.doi.org/10.18060/24223.

Texto completo da fonte

Resumo:

The Coalition of Urban and Metropolitan Universities (CUMU) celebrated its 25th annual conference in October 2019. Convening in Philadelphia PA, this conference was the largest for CUMU to date, selling out weeks in advance and drawing representatives from across the United States, Canada, and South Africa. With the theme of “All In: The Urban Mission”, attendees gathered purposefully to examine how universities are striving to intentionally align their goals with the priorities of their host cities to affect desired change, drive economic development and inclusion, and address issues of shared importance.

Estilos ABNT, Harvard, Vancouver, APA, etc.

14

Hockings, Helen, Michelle Lockley, Trevor Graham, Eszter Lakatos e Weini Huang. "Abstract B001: Developing adaptive therapy to suppress the evolution of treatment resistance in high-grade serous ovarian cancer". Cancer Research 82, n.º 10_Supplement (15 de maio de 2022): B001. http://dx.doi.org/10.1158/1538-7445.evodyn22-b001.

Texto completo da fonte

Resumo:

Abstract This abstract is being presented as a short talk in the scientific program. A full abstract is available in the Proffered Abstracts section (PR015) of the Conference Proceedings. Citation Format: Helen Hockings, Michelle Lockley, Trevor Graham, Eszter Lakatos, Weini Huang. Developing adaptive therapy to suppress the evolution of treatment resistance in high-grade serous ovarian cancer [abstract]. In: Proceedings of the AACR Special Conference on the Evolutionary Dynamics in Carcinogenesis and Response to Therapy; 2022 Mar 14-17. Philadelphia (PA): AACR; Cancer Res 2022;82(10 Suppl):Abstract nr B001.

Estilos ABNT, Harvard, Vancouver, APA, etc.

15

de Aragao Mendes, Adrianna Amaral, Hans Liu, Juhyung Woo, Kaushal Asrani, Avi Rosenberg, Pedram Argani e Tamara Lotan. "Abstract A019: Development and characterization of novel pre-clinical models of SFPQ-TFE3-driven renal cell carcinoma". Cancer Research 83, n.º 16_Supplement (15 de agosto de 2023): A019. http://dx.doi.org/10.1158/1538-7445.kidney23-a019.

Texto completo da fonte

Resumo:

Abstract This abstract is being presented as a short talk in the scientific program. A full abstract is printed in the Proffered Abstracts section (PR001) of the Conference Program/Proceedings. Citation Format: Adrianna Amaral de Aragao Mendes, Hans Liu, Juhyung Woo, Kaushal Asrani, Avi Rosenberg, Pedram Argani, Tamara Lotan. Development and characterization of novel pre-clinical models of SFPQ-TFE3-driven renal cell carcinoma [abstract]. In: Proceedings of the AACR Special Conference: Advances in Kidney Cancer Research; 2023 Jun 24-27; Austin, Texas. Philadelphia (PA): AACR; Cancer Res 2023;83(16 Suppl):Abstract nr A019.

Estilos ABNT, Harvard, Vancouver, APA, etc.

16

Zhuang, Xueqian, Simon Joost, Qing Wang, Melissa Blum, Selena Ding, Zhuxuan Li, Yingqian Zhan, Richard Koche, Emily Wong e Tuomas Tammela. "Abstract B019: Aging-induced reprogramming of the cell of origin defines lung cancer evolution". Cancer Research 83, n.º 2_Supplement_1 (15 de janeiro de 2023): B019. http://dx.doi.org/10.1158/1538-7445.agca22-b019.

Texto completo da fonte

Resumo:

Abstract This abstract is being presented as a short talk in the scientific program. A full abstract is available in the Short Talks from Proffered Abstracts section (PR010) of the Conference Proceedings. Citation Format: Xueqian Zhuang, Simon Joost, Qing Wang, Melissa Blum, Selena Ding, Zhuxuan Li, Yingqian Zhan, Richard Koche, Emily Wong, Tuomas Tammela. Aging-induced reprogramming of the cell of origin defines lung cancer evolution [abstract]. In: Proceedings of the AACR Special Conference: Aging and Cancer; 2022 Nov 17-20; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2022;83(2 Suppl_1):Abstract nr B019.

Estilos ABNT, Harvard, Vancouver, APA, etc.

17

Zhakula-Kostadinova, Nadja, Sejal Jain, Laura Byron, Matthew L. Meyerson e Alison M. Taylor. "Abstract B018: Investigating vulnerabilities associated with chromosome arm aneuploidy in cancer". Molecular Cancer Therapeutics 23, n.º 6_Supplement (10 de junho de 2024): B018. http://dx.doi.org/10.1158/1538-8514.synthleth24-b018.

Texto completo da fonte

Resumo:

Abstract This abstract is being presented as a short talk in the scientific program. A full abstract is printed in the Proffered Abstracts section (PR016) of the Conference Program/Proceedings. Citation Format: Nadja Zhakula-Kostadinova, Sejal Jain, Laura Byron, Matthew L. Meyerson, Alison M. Taylor. Investigating vulnerabilities associated with chromosome arm aneuploidy in cancer [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Expanding and Translating Cancer Synthetic Vulnerabilities; 2024 Jun 10-13; Montreal, Quebec, Canada. Philadelphia (PA): AACR; Mol Cancer Ther 2024;23(6 Suppl):Abstract nr B018.

Estilos ABNT, Harvard, Vancouver, APA, etc.

18

Alfaro-Murillo, Jorge A., Krishna Dasari e Jeffrey P. Townsend. "Abstract B011: Detecting pairwise and higher-order antagonistic epistatic effects among somatic cancer genotypes to discover synthetic lethality". Molecular Cancer Therapeutics 23, n.º 6_Supplement (10 de junho de 2024): B011. http://dx.doi.org/10.1158/1538-8514.synthleth24-b011.

Texto completo da fonte

Resumo:

Abstract This abstract is being presented as a short talk in the scientific program. A full abstract is printed in the Proffered Abstracts section (PR013) of the Conference Program/Proceedings. Citation Format: Jorge A. Alfaro-Murillo, Krishna Dasari, Jeffrey P Townsend. Detecting pairwise and higher-order antagonistic epistatic effects among somatic cancer genotypes to discover synthetic lethality [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Expanding and Translating Cancer Synthetic Vulnerabilities; 2024 Jun 10-13; Montreal, Quebec, Canada. Philadelphia (PA): AACR; Mol Cancer Ther 2024;23(6 Suppl):Abstract nr B011.

Estilos ABNT, Harvard, Vancouver, APA, etc.

19

Andersson, Natalie, Adriana Mañas Nuñez, Kristina Aaltonen, Karin Hansson, Alexandra Seger, Katarzyna Radke, Javanshir Esfandyari, Daniel Bexell e David Gisselsson. "Abstract A011: Deciphering clonal evolution under chemotherapy in high-risk neuroblastoma using patient derived models". Cancer Research 82, n.º 10_Supplement (15 de maio de 2022): A011. http://dx.doi.org/10.1158/1538-7445.evodyn22-a011.

Texto completo da fonte

Resumo:

Abstract This abstract is being presented as a short talk in the scientific program. A full abstract is available in the Proffered Abstracts section (PR001) of the Conference Proceedings. Citation Format: Natalie Andersson, Adriana Mañas Nuñez, Kristina Aaltonen, Karin Hansson, Alexandra Seger, Katarzyna Radke, Javanshir Esfandyari, Daniel Bexell, David Gisselsson. Deciphering clonal evolution under chemotherapy in high-risk neuroblastoma using patient derived models [abstract]. In: Proceedings of the AACR Special Conference on the Evolutionary Dynamics in Carcinogenesis and Response to Therapy; 2022 Mar 14-17. Philadelphia (PA): AACR; Cancer Res 2022;82(10 Suppl):Abstract nr A011.

Estilos ABNT, Harvard, Vancouver, APA, etc.

20

Avdieiev, Stanislav, Leticia Tordesillas, Omar Chavez Chiang, Zhihua Chen, Luiza Silva Simoes, Y. Ann Chen, Noemi Andor et al. "Abstract A017: In vivo tracking of clonal dynamics during UV-induced skin carcinogenesis". Cancer Research 82, n.º 10_Supplement (15 de maio de 2022): A017. http://dx.doi.org/10.1158/1538-7445.evodyn22-a017.

Texto completo da fonte

Resumo:

Abstract This abstract is being presented as a short talk in the scientific program. A full abstract is available in the Proffered Abstracts section (PR004) of the Conference Proceedings. Citation Format: Stanislav Avdieiev, Leticia Tordesillas, Omar Chavez Chiang, Zhihua Chen, Luiza Silva Simoes, Y. Ann Chen, Noemi Andor, Robert Gatenby, Elsa R. Flores, Joel S. Brown, Kenneth Y. Tsai. In vivo tracking of clonal dynamics during UV-induced skin carcinogenesis [abstract]. In: Proceedings of the AACR Special Conference on the Evolutionary Dynamics in Carcinogenesis and Response to Therapy; 2022 Mar 14-17. Philadelphia (PA): AACR; Cancer Res 2022;82(10 Suppl):Abstract nr A017.

Estilos ABNT, Harvard, Vancouver, APA, etc.

21

Gardner, Andrea, Lan Zheng, Kennedy Howland, Chisom Iloegbunam, Patrik Barrera, Carolina De Santiago e Amy Brock. "Abstract B017: Homotypic cell-cell fusion in TNBC cells downregulates cancer testis antigen MAGEC2 and increases therapeutic sensitivity to paclitaxel and doxorubicin". Cancer Research 82, n.º 10_Supplement (15 de maio de 2022): B017. http://dx.doi.org/10.1158/1538-7445.evodyn22-b017.

Texto completo da fonte

Resumo:

Abstract This abstract is being presented as a short talk in the scientific program. A full abstract is available in the Proffered Abstracts section (PR007) of the Conference Proceedings. Citation Format: Andrea Gardner, Lan Zheng, Kennedy Howland, Chisom Iloegbunam, Patrik Barrera, Carolina De Santiago, Amy Brock. Homotypic cell-cell fusion in TNBC cells downregulates cancer testis antigen MAGEC2 and increases therapeutic sensitivity to paclitaxel and doxorubicin [abstract]. In: Proceedings of the AACR Special Conference on the Evolutionary Dynamics in Carcinogenesis and Response to Therapy; 2022 Mar 14-17. Philadelphia (PA): AACR; Cancer Res 2022;82(10 Suppl):Abstract nr B017.

Estilos ABNT, Harvard, Vancouver, APA, etc.

22

Gatenbee, Chandler D., Ann-Marie Baker, Ryan O. Schenck, Maximilian Strobl, Jeffrey West, Mark Robertson-Tessi, Trevor A. Graham e Alexander R. A. Anderson. "Abstract B033: Immunosuppressive niche engineering at the onset of human colorectal cancer". Cancer Research 82, n.º 10_Supplement (15 de maio de 2022): B033. http://dx.doi.org/10.1158/1538-7445.evodyn22-b033.

Texto completo da fonte

Resumo:

Abstract This abstract is being presented as a short talk in the scientific program. A full abstract is available in the Proffered Abstracts section (PR0081) of the Conference Proceedings. Citation Format: Chandler D. Gatenbee, Ann-Marie Baker, Ryan O. Schenck, Maximilian Strobl, Jeffrey West, Mark Robertson-Tessi, Trevor A. Graham, Alexander R.A. Anderson. Immunosuppressive niche engineering at the onset of human colorectal cancer [abstract]. In: Proceedings of the AACR Special Conference on the Evolutionary Dynamics in Carcinogenesis and Response to Therapy; 2022 Mar 14-17. Philadelphia (PA): AACR; Cancer Res 2022;82(10 Suppl):Abstract nr B033.

Estilos ABNT, Harvard, Vancouver, APA, etc.

23

Giersch, Rachael M., Marisa A. Yonemitsu, Samuel F. M. Hart e Michael J. Metzger. "Abstract A023: Progression and regression dynamics of bivalve transmissible neoplasia in the soft-shell clam (Mya arenaria) after both natural and experimental exposure". Cancer Research 82, n.º 10_Supplement (15 de maio de 2022): A023. http://dx.doi.org/10.1158/1538-7445.evodyn22-a023.

Texto completo da fonte

Resumo:

Abstract This abstract is being presented as a short talk in the scientific program. A full abstract is available in the Proffered Abstracts section (PR017) of the Conference Proceedings. Citation Format: Rachael M. Giersch, Marisa A. Yonemitsu, Samuel F.M. Hart, Michael J. Metzger. Progression and regression dynamics of bivalve transmissible neoplasia in the soft-shell clam (Mya arenaria) after both natural and experimental exposure [abstract]. In: Proceedings of the AACR Special Conference on the Evolutionary Dynamics in Carcinogenesis and Response to Therapy; 2022 Mar 14-17. Philadelphia (PA): AACR; Cancer Res 2022;82(10 Suppl):Abstract nr A023.

Estilos ABNT, Harvard, Vancouver, APA, etc.

24

Braxton, Alicia M., Ashley Kiemen, Rachel Karchin, Yuchen Jiao, Pei-Hsun Wu, Ralph H. Hruban, Denis Wirtz e Laura D. Wood. "Abstract B027: Three-dimensional genomic analysis of human pancreatic intraepithelial neoplasia (PanIN) reveals striking multifocality and genetic heterogeneity". Cancer Research 82, n.º 22_Supplement (15 de novembro de 2022): B027. http://dx.doi.org/10.1158/1538-7445.panca22-b027.

Texto completo da fonte

Resumo:

Abstract This abstract is being presented as a short talk in the scientific program. A full abstract is available in the Short Talks from Proffered Abstracts section (PR007) of the Conference Proceedings. Citation Format: Alicia M. Braxton, Ashley Kiemen, Rachel Karchin, Yuchen Jiao, Pei-Hsun Wu, Ralph H Hruban, Denis Wirtz, Laura D. Wood. Three-dimensional genomic analysis of human pancreatic intraepithelial neoplasia (PanIN) reveals striking multifocality and genetic heterogeneity [abstract]. In: Proceedings of the AACR Special Conference on Pancreatic Cancer; 2022 Sep 13-16; Boston, MA. Philadelphia (PA): AACR; Cancer Res 2022;82(22 Suppl):Abstract nr B027.

Estilos ABNT, Harvard, Vancouver, APA, etc.

25

Mason, Frank M., Anteneh T. Tebeje, Emily S. Kounlavong, Rashmi Dahiya, Logan Vlach, Tiffany Guess, Ruhee Dere et al. "Abstract B016: SETD2 safeguards the genome against isochromosome formation". Cancer Research 83, n.º 16_Supplement (15 de agosto de 2023): B016. http://dx.doi.org/10.1158/1538-7445.kidney23-b016.

Texto completo da fonte

Resumo:

Abstract This abstract is being presented as a short talk in the scientific program. A full abstract is printed in the Proffered Abstracts section (PR012) of the Conference Program/Proceedings. Citation Format: Frank M. Mason, Anteneh T. Tebeje, Emily S. Kounlavong, Rashmi Dahiya, Logan Vlach, Tiffany Guess, Ruhee Dere, Ryoma Ohi, Peter Ly, Cheryl L. Walker, W. Kimryn Rathmell. SETD2 safeguards the genome against isochromosome formation [abstract]. In: Proceedings of the AACR Special Conference: Advances in Kidney Cancer Research; 2023 Jun 24-27; Austin, Texas. Philadelphia (PA): AACR; Cancer Res 2023;83(16 Suppl):Abstract nr B016.

Estilos ABNT, Harvard, Vancouver, APA, etc.

26

Miyano, Masaru, Rosalyn W. Sayaman, Parijat Senapati, Stefan Hinz, Victoria E. Seewaldt, Dustin Schones e Mark A. LaBarge. "Abstract A003: Integrating noise into a signal: Luminal epithelial cells integrate variable responses to aging into stereotypical changes that underlie breast cancer susceptibility". Cancer Research 83, n.º 2_Supplement_1 (15 de janeiro de 2023): A003. http://dx.doi.org/10.1158/1538-7445.agca22-a003.

Texto completo da fonte

Resumo:

Abstract This abstract is being presented as a short talk in the scientific program. A full abstract is available in the Short Talks from Proffered Abstracts section (PR006) of the Conference Proceedings. Citation Format: Masaru Miyano, Rosalyn W. Sayaman, Parijat Senapati, Stefan Hinz, Victoria E. Seewaldt, Dustin Schones, Mark A. LaBarge. Integrating noise into a signal: Luminal epithelial cells integrate variable responses to aging into stereotypical changes that underlie breast cancer susceptibility [abstract]. In: Proceedings of the AACR Special Conference: Aging and Cancer; 2022 Nov 17-20; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2022;83(2 Suppl_1):Abstract nr A003.

Estilos ABNT, Harvard, Vancouver, APA, etc.

27

Modiano, Jaime F., Ashley J. Schulte, Taylor A. DaPauw, Ali Khammanivong, Jong H. Kim, Aaron L. Sarver, Gary R. Cutter, Eric Lindquist e Kelly M. Makielski. "Abstract A004: Identification and characterization of the cancer permissive environment in companion dogs". Cancer Research 83, n.º 2_Supplement_1 (15 de janeiro de 2023): A004. http://dx.doi.org/10.1158/1538-7445.agca22-a004.

Texto completo da fonte

Resumo:

Abstract This abstract is being presented as a short talk in the scientific program. A full abstract is available in the Short Talks from Proffered Abstracts section (PR008) of the Conference Proceedings. Citation Format: Jaime F. Modiano, Ashley J. Schulte, Taylor A. DaPauw, Ali Khammanivong, Jong H. Kim, Aaron L. Sarver, Gary R. Cutter, Eric Lindquist, Kelly M. Makielski. Identification and characterization of the cancer permissive environment in companion dogs [abstract]. In: Proceedings of the AACR Special Conference: Aging and Cancer; 2022 Nov 17-20; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2022;83(2 Suppl_1):Abstract nr A004.

Estilos ABNT, Harvard, Vancouver, APA, etc.

28

Zhang, Yuxia, Virginia Ojeda, Xiaobo Wang, Ken Dunner, Filippo Giancotti, Hao Zhou, Jonathan Hernandez e Steven Q. Xu. "Abstract A029: Merlin/NF2 inhibits pancreatic cancer metastasis by activation of AMPK-dependent autophagic degradation of p62". Cancer Research 84, n.º 3_Supplement_2 (1 de fevereiro de 2024): A029. http://dx.doi.org/10.1158/1538-7445.canevol23-a029.

Texto completo da fonte

Resumo:

Abstract This abstract is being presented as a short talk in the scientific program. A full abstract is printed in the Proffered Abstracts section (PR004) of the Conference Program/Proceedings. Citation Format: Yuxia Zhang, Virginia Ojeda, Xiaobo Wang, Ken Dunner, Filippo Giancotti, Hao Zhou, Jonathan Hernandez, Steven Q. Xu. Merlin/NF2 inhibits pancreatic cancer metastasis by activation of AMPK-dependent autophagic degradation of p62 [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Translating Cancer Evolution and Data Science: The Next Frontier; 2023 Dec 3-6; Boston, Massachusetts. Philadelphia (PA): AACR; Cancer Res 2024;84(3 Suppl_2):Abstract nr A029.

Estilos ABNT, Harvard, Vancouver, APA, etc.

29

Olsen, Sarah Naomi, Bryn Anderson, Charles Hatton, Rinath Jeselsohn, Myles Brown, Eneda Toska e Scott Armstrong. "Abstract A025: KAT6A/B and Menin-MLL complexes coordinately regulate estrogen receptor-driven gene expression programs in breast cancer". Molecular Cancer Therapeutics 23, n.º 6_Supplement (10 de junho de 2024): A025. http://dx.doi.org/10.1158/1538-8514.synthleth24-a025.

Texto completo da fonte

Resumo:

Abstract This abstract is being presented as a short talk in the scientific program. A full abstract is printed in the Proffered Abstracts section (PR012) of the Conference Program/Proceedings. Citation Format: Sarah Naomi Olsen, Bryn Anderson, Charles Hatton, Rinath Jeselsohn, Myles Brown, Eneda Toska, Scott Armstrong. KAT6A/B and Menin-MLL complexes coordinately regulate estrogen receptor-driven gene expression programs in breast cancer [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Expanding and Translating Cancer Synthetic Vulnerabilities; 2024 Jun 10-13; Montreal, Quebec, Canada. Philadelphia (PA): AACR; Mol Cancer Ther 2024;23(6 Suppl):Abstract nr A025.

Estilos ABNT, Harvard, Vancouver, APA, etc.

30

Deng, Qiyun, Mehdi Amiri, Anastasija Ana Piric, Yasaman Bagherian, Zilan Li, Sidong Huang, Michael Pollak e Nahum Sonenberg. "Abstract A014: Inhibiting eIF4E phosphorylation sensitizes triple-negative breast cancer to CDK4/6 inhibition". Molecular Cancer Therapeutics 23, n.º 6_Supplement (10 de junho de 2024): A014. http://dx.doi.org/10.1158/1538-8514.synthleth24-a014.

Texto completo da fonte

Resumo:

Abstract This abstract is being presented as a short talk in the scientific program. A full abstract is printed in the Proffered Abstracts section (PR011) of the Conference Program/Proceedings. Citation Format: Qiyun Deng, Mehdi Amiri, Anastasija Ana Piric, Yasaman Bagherian, Zilan Li, Sidong Huang, Michael Pollak, Nahum Sonenberg. Inhibiting eIF4E phosphorylation sensitizes triple-negative breast cancer to CDK4/6 inhibition [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Expanding and Translating Cancer Synthetic Vulnerabilities; 2024 Jun 10-13; Montreal, Quebec, Canada. Philadelphia (PA): AACR; Mol Cancer Ther 2024;23(6 Suppl):Abstract nr A014.

Estilos ABNT, Harvard, Vancouver, APA, etc.

31

Chen, Richard J., Drew F. K. Williamson, Ming Y. Lu, Tiffany Y. Chen, Jana Lipkova, Muhammad Shaban e Faisal Mahmood. "Abstract A007: Racial disparities bias oncology AI models". Cancer Epidemiology, Biomarkers & Prevention 32, n.º 1_Supplement (1 de janeiro de 2023): A007. http://dx.doi.org/10.1158/1538-7755.disp22-a007.

Texto completo da fonte

Resumo:

Abstract Deep learning-based computational pathology models can be trained to make accurate diagnostic, prognostic, and therapeutic response predictions. Such models have also recently received regulatory approval in Europe and in the US. However, a majority of these models are trained and independently evaluated on large repositories of data representative of overall patient populations without extensive evaluation on underrepresented minorities or other subgroups. Here we show that such pathology AI models can be biased when independent and external evaluation test sets are stratified by race, demonstrating the need for more extensive evaluation of such models before regulatory approvals Citation Format: Richard J. Chen, Drew F.K. Williamson, Ming Y. Lu, Tiffany Y. Chen, Jana Lipkova, Muhammad Shaban, Faisal Mahmood. Racial disparities bias oncology AI models [abstract]. In: Proceedings of the 15th AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved; 2022 Sep 16-19; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2022;31(1 Suppl):Abstract nr A007.

Estilos ABNT, Harvard, Vancouver, APA, etc.

32

Shokat, Kevan M. "Abstract IA08: Direct covalent inhibitors of mutant K-Ras". Molecular Cancer Research 21, n.º 5_Supplement (1 de maio de 2023): IA08. http://dx.doi.org/10.1158/1557-3125.ras23-ia08.

Texto completo da fonte

Resumo:

Abstract Somatic mutations in the small GTPase K-Ras are the most common activating lesions found in human cancer, and are generally associated with poor response to standard therapies. Efforts to directly target this oncogene have faced difficulties due to its picomolar affinity for GTP/GDP and the absence of known allosteric regulatory sites. I will discuss the development of small molecules that irreversibly bind to a common oncogenic mutant, K-Ras G12C. These compounds rely on the mutant cysteine for binding and therefore do not affect the wild type protein (WT). New covalent molecules targeting K-Ras G12S and G12D are currently under development and will be discussed. I will also discuss reactivation of mutant p53 (Y220C) to leverage the natural anti-tumor effects of tumor suppressors. Citation Format: Kevan M. Shokat. Direct covalent inhibitors of mutant K-Ras [abstract]. In: Proceedings of the AACR Special Conference: Targeting RAS; 2023 Mar 5-8; Philadelphia, PA. Philadelphia (PA): AACR; Mol Cancer Res 2023;21(5_Suppl):Abstract nr IA08.

Estilos ABNT, Harvard, Vancouver, APA, etc.

33

Hahn, William C. "Abstract IA25: Systematic interrogation of KRAS function". Molecular Cancer Research 21, n.º 5_Supplement (1 de maio de 2023): IA25. http://dx.doi.org/10.1158/1557-3125.ras23-ia25.

Texto completo da fonte

Resumo:

Abstract Oncogenic mutations of KRAS occur frequently in pancreas, lung and colon cancers. Recent efforts to target particular KRAS alleles or RAS effector pathways has led to clinical responses but resistance to therapy limits the effectiveness of these therapies. To understand the role of KRAS in tumor initiation and maintenance, we have used systematic approaches to understand dependencies in KRAS-driven cancers. Specifically, we have used genome scale gain and loss of function screens to interrogate pathways necessary for the survival of KRAS-driven cancers. We have identified genes that required for the survival of KRAS-driven cancers and that canonical RAS signaling proteins have multiple functions. Together these on-going approaches provide new insights into KRAS signaling and identify potential targets for combination therapies for KRAS driven cancers. Citation Format: William C. Hahn. Systematic interrogation of KRAS function [abstract]. In: Proceedings of the AACR Special Conference: Targeting RAS; 2023 Mar 5-8; Philadelphia, PA. Philadelphia (PA): AACR; Mol Cancer Res 2023;21(5_Suppl):Abstract nr IA25.

Estilos ABNT, Harvard, Vancouver, APA, etc.

34

Lahtinen, Alexandra, Kari Lavikka, Yilin Li, Sanaz Jamalzadeh, Anni Virtanen, Rainer Lehtonen, Olli Carpén et al. "Abstract A010: Integration of clonal composition and tumor heterogeneity reveals novel evolutionary states and intervention targets in ovarian cancer". Cancer Research 82, n.º 10_Supplement (15 de maio de 2022): A010. http://dx.doi.org/10.1158/1538-7445.evodyn22-a010.

Texto completo da fonte

Resumo:

Abstract This abstract is being presented as a short talk in the scientific program. A full abstract is available in the Proffered Abstracts section (PR003) of the Conference Proceedings. Citation Format: Alexandra Lahtinen, Kari Lavikka, Yilin Li, Sanaz Jamalzadeh, Anni Virtanen, Rainer Lehtonen, Olli Carpén, Sakari Hietanen, Kaisa Huhtinen, Antti Häkkinen, Johanna Hynninen, Jaana Oikkonen, Sampsa Hautaniemi. Integration of clonal composition and tumor heterogeneity reveals novel evolutionary states and intervention targets in ovarian cancer [abstract]. In: Proceedings of the AACR Special Conference on the Evolutionary Dynamics in Carcinogenesis and Response to Therapy; 2022 Mar 14-17. Philadelphia (PA): AACR; Cancer Res 2022;82(10 Suppl):Abstract nr A010.

Estilos ABNT, Harvard, Vancouver, APA, etc.

35

Hirosue, Shoko, Jianfeng Ge, Leticia Castillon, Paulo Rodrigues, Dóra Bihary, Alyson Speed, Ludovic Wesolowski et al. "Abstract A015: Injury-associated transcriptional state transitions in early renal carcinogenesis". Cancer Research 83, n.º 16_Supplement (15 de agosto de 2023): A015. http://dx.doi.org/10.1158/1538-7445.kidney23-a015.

Texto completo da fonte

Resumo:

Abstract This abstract is being presented as a short talk in the scientific program. A full abstract is printed in the Proffered Abstracts section (PR002) of the Conference Program/Proceedings. Citation Format: Shoko Hirosue, Jianfeng Ge, Leticia Castillon, Paulo Rodrigues, Dóra Bihary, Alyson Speed, Ludovic Wesolowski, Veronica Caraffini, Anne Y. Warren, Grant D. Stewart, Sarah J. Welsh, Thomas J. Mitchell, Athena Matakidou, Fatemeh S. Seyednasrollah, Shamith A. Samarajiwa, Sakari Vanharanta. Injury-associated transcriptional state transitions in early renal carcinogenesis [abstract]. In: Proceedings of the AACR Special Conference: Advances in Kidney Cancer Research; 2023 Jun 24-27; Austin, Texas. Philadelphia (PA): AACR; Cancer Res 2023;83(16 Suppl):Abstract nr A015.

Estilos ABNT, Harvard, Vancouver, APA, etc.

36

Chen, Guangbo, Hong Zheng, Yael Rosenberg-Hasson, Saron Araya, Cindy Padilla, Kavita Sarin, Cornelia L. Dekker et al. "Abstract A014: Cytokines surge in the blood years prior to a cancer diagnosis in elderly individuals". Cancer Research 83, n.º 2_Supplement_1 (15 de janeiro de 2023): A014. http://dx.doi.org/10.1158/1538-7445.agca22-a014.

Texto completo da fonte

Resumo:

Abstract This abstract is being presented as a short talk in the scientific program. A full abstract is available in the Short Talks from Proffered Abstracts section (PR002) of the Conference Proceedings. Citation Format: Guangbo Chen, Hong Zheng, Yael Rosenberg-Hasson, Saron Araya, Cindy Padilla, Kavita Sarin, Cornelia L. Dekker, Philip Grant, Holden T. Maecker, David Furman, Shai Shen-Orr, Purvesh Khatri, Mark M. Davis. Cytokines surge in the blood years prior to a cancer diagnosis in elderly individuals [abstract]. In: Proceedings of the AACR Special Conference: Aging and Cancer; 2022 Nov 17-20; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2022;83(2 Suppl_1):Abstract nr A014.

Estilos ABNT, Harvard, Vancouver, APA, etc.

37

Li, Peng, Yuanli Zhen, Chiho Kim, Zhengshuai Liu, Jianwei Hao, Heping Deng, Hejun Deng et al. "Abstract B023: Nimbolide targets RNF114 to induce the trapping of PARP1 and synthetic lethality in BRCA-mutated cancer". Molecular Cancer Therapeutics 23, n.º 6_Supplement (10 de junho de 2024): B023. http://dx.doi.org/10.1158/1538-8514.synthleth24-b023.

Texto completo da fonte

Resumo:

Abstract This abstract is being presented as a short talk in the scientific program. A full abstract is printed in the Proffered Abstracts section (PR002) of the Conference Program/Proceedings. Citation Format: Peng Li, Yuanli Zhen, Chiho Kim, Zhengshuai Liu, Jianwei Hao, Heping Deng, Hejun Deng, Min Zhou, Xu-Dong Wang, Tian Qin, Yonghao Yu. Nimbolide targets RNF114 to induce the trapping of PARP1 and synthetic lethality in BRCA-mutated cancer [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Expanding and Translating Cancer Synthetic Vulnerabilities; 2024 Jun 10-13; Montreal, Quebec, Canada. Philadelphia (PA): AACR; Mol Cancer Ther 2024;23(6 Suppl):Abstract nr B023.

Estilos ABNT, Harvard, Vancouver, APA, etc.

38

Milne, Julia V., Ebtihal Mustafa, Kenji Fujihara, Eric Kusnadi, Anna Trigos, Niko Thio, Maree Pechlivanis et al. "Abstract A006: Delineating functional drivers of esophageal adenocarcinoma to identify synthetic lethal interactions". Molecular Cancer Therapeutics 23, n.º 6_Supplement (10 de junho de 2024): A006. http://dx.doi.org/10.1158/1538-8514.synthleth24-a006.

Texto completo da fonte

Resumo:

Abstract This abstract is being presented as a short talk in the scientific program. A full abstract is printed in the Proffered Abstracts section (PR007) of the Conference Program/Proceedings. Citation Format: Julia V Milne, Ebtihal Mustafa, Kenji Fujihara, Eric Kusnadi, Anna Trigos, Niko Thio, Maree Pechlivanis, Carlos Cabalag, Twishi Gulati, Kaylene Simpson, Cuong Duong, Luc Furic, Wayne Phillips, Nicholas Clemons. Delineating functional drivers of esophageal adenocarcinoma to identify synthetic lethal interactions [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Expanding and Translating Cancer Synthetic Vulnerabilities; 2024 Jun 10-13; Montreal, Quebec, Canada. Philadelphia (PA): AACR; Mol Cancer Ther 2024;23(6 Suppl):Abstract nr A006.

Estilos ABNT, Harvard, Vancouver, APA, etc.

39

Arafeh, Rand, Laura Chang, Lydia Sawyer, Helen Wang, James McFarland, Joshua Dempster, Peter DeWeirdt, John Doench e William C. Hahn. "Abstract B015: Combinatorial genetic screens to map synthetic lethal interactions and identify new cancer drug targets in KRAS mutant cancers". Molecular Cancer Therapeutics 23, n.º 6_Supplement (10 de junho de 2024): B015. http://dx.doi.org/10.1158/1538-8514.synthleth24-b015.

Texto completo da fonte

Resumo:

Abstract This abstract is being presented as a short talk in the scientific program. A full abstract is printed in the Proffered Abstracts section (PR014) of the Conference Program/Proceedings. Citation Format: Rand Arafeh, Laura Chang, Lydia Sawyer, Helen Wang, James McFarland, Joshua Dempster, Peter DeWeirdt, John Doench, William C Hahn. Combinatorial genetic screens to map synthetic lethal interactions and identify new cancer drug targets in KRAS mutant cancers [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Expanding and Translating Cancer Synthetic Vulnerabilities; 2024 Jun 10-13; Montreal, Quebec, Canada. Philadelphia (PA): AACR; Mol Cancer Ther 2024;23(6 Suppl):Abstract nr B015.

Estilos ABNT, Harvard, Vancouver, APA, etc.

40

Yeh, Jen Jen. "Abstract IA011: Precision oncology approaches in pancreatic cancer". Cancer Research 82, n.º 22_Supplement (15 de novembro de 2022): IA011. http://dx.doi.org/10.1158/1538-7445.panca22-ia011.

Texto completo da fonte

Resumo:

Abstract Advances in next generation sequencing and therapies have led to an explosion of possibilities for precision oncology in pancreatic cancer. The talk will focus on current and up and coming precision approaches for patients with pancreatic cancer. Citation Format: Jen Jen Yeh. Precision oncology approaches in pancreatic cancer [abstract]. In: Proceedings of the AACR Special Conference on Pancreatic Cancer; 2022 Sep 13-16; Boston, MA. Philadelphia (PA): AACR; Cancer Res 2022;82(22 Suppl):Abstract nr IA011.

Estilos ABNT, Harvard, Vancouver, APA, etc.

41

Mousseau, Richard J. "Abstract IA018: “Pursuing Wicozani for the Oceti Sakowin”: Reducing cancer disparities among AI/AN in the Great Plains". Cancer Epidemiology, Biomarkers & Prevention 32, n.º 1_Supplement (1 de janeiro de 2023): IA018. http://dx.doi.org/10.1158/1538-7755.disp22-ia018.

Texto completo da fonte

Resumo:

Abstract American Indian and Alaska Native (AI/AN) populations are among the underserved minority groups in the country and have the lowest survival rates for nearly all types of cancer of any subpopulation in the United States. Great Plains AI/AN populations have the highest age-adjusted cancers mortality compared to Native Americans from any other region. Addressing disparities in cancer outcomes among Great Plains AI/AN populations poses challenges in transportation, access to services, linguistic, and cultural variates. The Great Plains Tribal Leaders Health Board Community Health Department offers a variety of programs and projects to address these challenges and reduce these cancer disparities. Citation Format: Richard J. Mousseau. “Pursuing Wicozani for the Oceti Sakowin”: Reducing cancer disparities among AI/AN in the Great Plains [abstract]. In: Proceedings of the 15th AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved; 2022 Sep 16-19; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2022;31(1 Suppl):Abstract nr IA018.

Estilos ABNT, Harvard, Vancouver, APA, etc.

42

Lehman, Connie. "Abstract IA022: Imaging tools for DCIS: Past, present and future". Cancer Prevention Research 15, n.º 12_Supplement_1 (1 de dezembro de 2022): IA022. http://dx.doi.org/10.1158/1940-6215.dcis22-ia022.

Texto completo da fonte

Resumo:

Abstract In the past, mammography was considered the imaging test of choice to identify DCIS. More recent studies clarified breast MRI is more sensitive than mammography to identify DCIS overall and higher grade DCIS specifically. Techniques to support Fast or Abbreviated MRI were developed to try to support greater access, lower costs, increased patient acceptance of breast MRI in both the screening and the diagnostic setting. In the future, contrast enhanced mammography may provide greater access to more patients to the benefits of vascular imaging of DCIS, benefits previously limited to contrast enhanced breast MRI. Deep learning models in the domain of Artificial Intelligence may support more accurate triage of DCIS lesions more and less likely to progress, supporting more effective triage of low risk DCIS lesions to surveillance. Citation Format: Connie Lehman. Imaging tools for DCIS: Past, present and future [abstract]. In: Proceedings of the AACR Special Conference on Rethinking DCIS: An Opportunity for Prevention?; 2022 Sep 8-11; Philadelphia, PA. Philadelphia (PA): AACR; Can Prev Res 2022;15(12 Suppl_1): Abstract nr IA022.

Estilos ABNT, Harvard, Vancouver, APA, etc.

43

Polyak, Kornelia. "Abstract IA035: DCIS to IDC progression - a key step of immune escape". Cancer Prevention Research 15, n.º 12_Supplement_1 (1 de dezembro de 2022): IA035. http://dx.doi.org/10.1158/1940-6215.dcis22-ia035.

Texto completo da fonte

Resumo:

Abstract The cellular and molecular mechanisms underlying ductal carcinoma in situ (DCIS) to invasive ductal carcinoma (IDC) transition are poorly understood. We have analyzed genetic, gene expression, epigenetic profiles of cells composing the tumor and identified cell type-specific changes during tumor progression. Importantly, we detected significant changes in the immune cell composition during tumor progression implying immune escape in invasive tumors and active adaptive immune response in DCIS. We demonstrate that these progression stage-specific alterations are also present in a rat model of breast cancer and that combined targeting of multiple components of the tumor ecosystem increases the efficacy of anti-cancer therapies. Our data highlight the role of microenvironmental, especially immune-related changes in driving breast tumor progression and emphasize the importance of studying pre-invasive tumors. Citation Format: Kornelia Polyak. DCIS to IDC progression - a key step of immune escape [abstract]. In: Proceedings of the AACR Special Conference on Rethinking DCIS: An Opportunity for Prevention?; 2022 Sep 8-11; Philadelphia, PA. Philadelphia (PA): AACR; Can Prev Res 2022;15(12 Suppl_1): Abstract nr IA035.

Estilos ABNT, Harvard, Vancouver, APA, etc.

44

Bar-Sagi, Dafna. "Abstract IA21: Immune rewiring of mutant Ras tumors: Mechanisms and translational implications". Molecular Cancer Research 21, n.º 5_Supplement (1 de maio de 2023): IA21. http://dx.doi.org/10.1158/1557-3125.ras23-ia21.

Texto completo da fonte

Resumo:

Abstract Oncogenic mutations in KRas are found in more than 90% of pancreatic tumors. These mutations are acquired at an early stage of disease and, in experimental models, have been shown to be essential for tumor initiation, progression and maintenance. Studies from our lab have shown that the growth of oncogenic KRas harboring pancreatic tumors is associated with an immuo-suppressed state that is established via the dynamic interplay between the tumor cells and the immune milieu. Molecular dissection of the mechanisms that mediate this interplay reveals the engagement of a transcriptional program that drives the expression of a plethora of cytokines and chemokines. This presentation will focus on a subgroup of cytokines and the role they play in activating specific immunosuppressive pathways. The implication of our findings to disease progression and therapeutic intervention will be discussed. Citation Format: Dafna Bar-Sagi. Immune rewiring of mutant Ras tumors: Mechanisms and translational implications [abstract]. In: Proceedings of the AACR Special Conference: Targeting RAS; 2023 Mar 5-8; Philadelphia, PA. Philadelphia (PA): AACR; Mol Cancer Res 2023;21(5_Suppl):Abstract nr IA21.

Estilos ABNT, Harvard, Vancouver, APA, etc.

45

Robertson-Tessi, Mark, Joel Brown, Maria Poole, Kimberly Luddy, Andriy Marusyk, Jill Gallaher, Jeffrey West et al. "Abstract B006: Evolutionary Tumor Board: Implementing dynamic personalized therapy using evolutionary theory and mathematical modeling for clinical decision support". Cancer Research 82, n.º 10_Supplement (15 de maio de 2022): B006. http://dx.doi.org/10.1158/1538-7445.evodyn22-b006.

Texto completo da fonte

Resumo:

Abstract This abstract is being presented as a short talk in the scientific program. A full abstract is available in the Proffered Abstracts section (PR010) of the Conference Proceedings. Citation Format: Mark Robertson-Tessi, Joel Brown, Maria Poole, Kimberly Luddy, Andriy Marusyk, Jill Gallaher, Jeffrey West, Matthew Johnson, Heiko Enderling, Rikesh Makanji, Joaquim Farinhas, Robert Gatenby, Damon Reed, Christine Chung, Alexander Anderson. Evolutionary Tumor Board: Implementing dynamic personalized therapy using evolutionary theory and mathematical modeling for clinical decision support [abstract]. In: Proceedings of the AACR Special Conference on the Evolutionary Dynamics in Carcinogenesis and Response to Therapy; 2022 Mar 14-17. Philadelphia (PA): AACR; Cancer Res 2022;82(10 Suppl):Abstract nr B006.

Estilos ABNT, Harvard, Vancouver, APA, etc.

46

Ahmed, Atique U., Jack M. Shireman, Fatemeh Atash, Gina Lee, Eunus S. Ali, Miranda R. Saathoff, Cheol H. Park et al. "Abstract B034: Targeting cellular plasticity-driven metabolic adaptation to overcome chemoresistance in GBM". Cancer Research 82, n.º 10_Supplement (15 de maio de 2022): B034. http://dx.doi.org/10.1158/1538-7445.evodyn22-b034.

Texto completo da fonte

Resumo:

Abstract This abstract is being presented as a short talk in the scientific program. A full abstract is available in the Proffered Abstracts section (PR011) of the Conference Proceedings. Citation Format: Atique U. Ahmed, Jack M. Shireman, Fatemeh Atash, Gina Lee, Eunus S. Ali, Miranda R. Saathoff, Cheol H. Park, Sol Savchuk, Shivani Baisiwala, Jason Miska, Maciej S. Lesniak, C. David James, Roger Stupp, Priya Kumthekar, Craig M. Horbinski, Issam Ben-Sahra. Targeting cellular plasticity-driven metabolic adaptation to overcome chemoresistance in GBM [abstract]. In: Proceedings of the AACR Special Conference on the Evolutionary Dynamics in Carcinogenesis and Response to Therapy; 2022 Mar 14-17. Philadelphia (PA): AACR; Cancer Res 2022;82(10 Suppl):Abstract nr B034.

Estilos ABNT, Harvard, Vancouver, APA, etc.

47

Challoner, Benjamin R., Andrew Woolston, David Lau, Marta Buzzetti, Louise J. Barber, Tom Lund, Harold B. Sansano et al. "Abstract A002: Genetic and immune landscape evolution defines subtypes of MMR deficient colorectal cancer". Cancer Research 82, n.º 10_Supplement (15 de maio de 2022): A002. http://dx.doi.org/10.1158/1538-7445.evodyn22-a002.

Texto completo da fonte

Resumo:

Abstract This abstract is being presented as a short talk in the scientific program. A full abstract is available in the Proffered Abstracts section (PR012) of the Conference Proceedings. Citation Format: Benjamin R. Challoner, Andrew Woolston, David Lau, Marta Buzzetti, Louise J. Barber, Tom Lund, Harold B. Sansano, Katharina von Loga, Héctor Lázare-Iglesias, Ruwaida Begum, Richard Crux, David Cunningham, Ian Chau, Naureen Starling, Juan Ruiz-Bañobre, Tony Dhillon, Marco Gerlinger. Genetic and immune landscape evolution defines subtypes of MMR deficient colorectal cancer [abstract]. In: Proceedings of the AACR Special Conference on the Evolutionary Dynamics in Carcinogenesis and Response to Therapy; 2022 Mar 14-17. Philadelphia (PA): AACR; Cancer Res 2022;82(10 Suppl):Abstract nr A002.

Estilos ABNT, Harvard, Vancouver, APA, etc.

48

Madrigal, Ariel, Minjun Kim, Adrien Osakwe, Tianyuan Lu, Zohreh Mehrjoo, Elham Moslemi, Rick Farouni et al. "Abstract B011: An atlas of cellular heterogeneity in primary and metastatic renal cell carcinomas". Cancer Research 83, n.º 16_Supplement (15 de agosto de 2023): B011. http://dx.doi.org/10.1158/1538-7445.kidney23-b011.

Texto completo da fonte

Resumo:

Abstract This abstract is being presented as a short talk in the scientific program. A full abstract is printed in the Proffered Abstracts section (PR005) of the Conference Program/Proceedings. Citation Format: Ariel Madrigal, Minjun Kim, Adrien Osakwe, Tianyuan Lu, Zohreh Mehrjoo, Elham Moslemi, Rick Farouni, Larisa Morales-Soto, Yu Chang Wang, Matthew Dankner, Haig Djambazian, Kevin Petrecca, Jonathan Spicer, Fadi Brimo, Peter Siegel, Morag Park, Jiannis Ragoussis, Simon Tanguay, Yasser Riazalhosseini, Hamed S. Najafabadi. An atlas of cellular heterogeneity in primary and metastatic renal cell carcinomas [abstract]. In: Proceedings of the AACR Special Conference: Advances in Kidney Cancer Research; 2023 Jun 24-27; Austin, Texas. Philadelphia (PA): AACR; Cancer Res 2023;83(16 Suppl):Abstract nr B011.

Estilos ABNT, Harvard, Vancouver, APA, etc.

49

Borges, Gabriel Alvares, Angelo Jose Guilatco, Christine M. Hachfeld, Ming Ruan, Sonya Royzenblat, Ming Xu, Claire M. Edwards et al. "Abstract B020: Pre-malignant plasma cells exhibit a senescence-like phenotype and accumulation of transposable elements". Cancer Research 83, n.º 2_Supplement_1 (15 de janeiro de 2023): B020. http://dx.doi.org/10.1158/1538-7445.agca22-b020.

Texto completo da fonte

Resumo:

Abstract This abstract is being presented as a short talk in the scientific program. A full abstract is available in the Short Talks from Proffered Abstracts section (PR012) of the Conference Proceedings. Citation Format: Gabriel Alvares Borges, Angelo Jose Guilatco, Christine M. Hachfeld, Ming Ruan, Sonya Royzenblat, Ming Xu, Claire M. Edwards, Marta Diaz-delCastillo, Thomas L. Andersen, Taxiarchis Kourelis, Tamar Tchkonia, James L. Kirkland, Matthew T. Drake, Megan Weivoda. Pre-malignant plasma cells exhibit a senescence-like phenotype and accumulation of transposable elements [abstract]. In: Proceedings of the AACR Special Conference: Aging and Cancer; 2022 Nov 17-20; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2022;83(2 Suppl_1):Abstract nr B020.

Estilos ABNT, Harvard, Vancouver, APA, etc.

50

Lan, Tuo, Mei Wang, AnnaLynn M. Williams, Matthew J. Ehrhardt, Emily R. Finch, Jennifer Q. Lanctot, Shu Jiang et al. "Abstract B004: Sugar Intake and premature aging in adult survivors of childhood cancer in the St. Jude Lifetime (SJLIFE) Cohort". Cancer Research 83, n.º 2_Supplement_1 (15 de janeiro de 2023): B004. http://dx.doi.org/10.1158/1538-7445.agca22-b004.

Texto completo da fonte

Resumo:

Abstract This abstract is being presented as a short talk in the scientific program. A full abstract is available in the Short Talks from Proffered Abstracts section (PR014) of the Conference Proceedings. Citation Format: Tuo Lan, Mei Wang, AnnaLynn M. Williams, Matthew J. Ehrhardt, Emily R. Finch, Jennifer Q. Lanctot, Shu Jiang, Kevin R. Krull, Gregory T. Armstrong, Melissa M. Hudson, Graham A. Colditz, Leslie Robison, Kirsten K. Ness, Yikyung Park. Sugar Intake and premature aging in adult survivors of childhood cancer in the St. Jude Lifetime (SJLIFE) Cohort [abstract]. In: Proceedings of the AACR Special Conference: Aging and Cancer; 2022 Nov 17-20; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2022;83(2 Suppl_1):Abstract nr B004.

Estilos ABNT, Harvard, Vancouver, APA, etc.

Artigos de revistas sobre o tema "Conference (1926 : Philadelphia, Pa.)"

Crie uma referência precisa em APA, MLA, Chicago, Harvard, e outros estilos